ArticleThe Journal of dermatology2026
Cutaneous and Subcutaneous Hyalohyphomycosis Caused by Purpureocillium Lilacinum in a Tertiary Referral Hospital in Central China.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpureocillium lilacinum, a saprobic filamentous fungus with a global distribution, is an emerging opportunistic pathogen, but its clinical and microbiological profile in China is not well characterized. This study retrospectively analyzed three cases of Purpureocillium lilacinum hyalohyphomycosis in central China and reviewed 7 additional cases from mainland China (2010-2025). The diagnosis was made through a meticulous integration of histopathological analysis, cultivation characteristics, Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS), and internal transcribed spacer (ITS) sequencing. All isolates had high minimum inhibitory concentrations (MICs) to amphotericin B, echinocandins, and fluconazole. Voriconazole and posaconazole showed the highest in vitro activity (MICs 0.12-1 mg/L and 0.25-0.5 mg/L, respectively), while itraconazole susceptibility varied (MIC 0.5-4 mg/L). Rapid and accurate identification requires confirmation via histopathology combined with MALDI-TOF MS or molecular diagnostic methods. Successful management relies on early suspicion, susceptibility-guided therapy with voriconazole and posaconazole, and surgical intervention when appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.